• 1
    Rankin GB. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am 1990; 74: 3950.
  • 2
    Levine JB. Extraintestinal manifestations of inflammatory bowel disease. In: KirsnerJB, ed. Inflammatory Bowel Disease, 5th edn. Philadelphia, PA: WB Saunder, 2000: 397409.
  • 3
    Eaden J, Abrams K, Ekbon A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Ther 2003; 17: 120714.
  • 4
    Rutter M, Saunders B, Wilkinson K. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 118: 6714.
  • 5
    Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 31421.
  • 6
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 48797.
  • 7
    Kane SV. Adherence issues in management of inflammatory bowel disease. In: BaylessTM, HanauerSB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, BC: Decker Inc., 2001: pp. 911.
  • 8
    Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 14718.
  • 9
    Farup P, Hinterleitner T, Lukas M. Mesalazine 4 gr daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 23742.
  • 10
    Hanauer SB, Sninsky CA, Robinson M. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 20411.
  • 11
    Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5 ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005; 11: 4217.
  • 12
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 13
    Kane S, Huo D, Aikens J, Hanauer S. Medication non-adherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 14
    Kane S, Cohen RD, Aikens JE, Hanauer S. Prevalence of non-adherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 15
    Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimes. Am J Gastroenterol 1999; 94: 173342.
    Direct Link:
  • 16
    Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol Ther 2006; 24: 1099103.
  • 17
    Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 21659.
  • 18
    Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150: 150910.
  • 19
    Kane S. Medication adherence and the physician–patient relationship. Am J Gastroenterol 2002; 97 (Suppl. 7): 1853.
    Direct Link:
  • 20
    Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 110.
    Direct Link:
  • 21
    Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-side ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13: 3818.
  • 22
    Kane S, Hanauer SB. National adherence rates with IBD therapy: PO vs PR [abstract]. Am J Gastroenterol 2001; 96: S296.
  • 23
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once-daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 1703.
  • 24
    Tebbi CK, Cummings KM, Zevon MA, Smith L, Richards M, Mallon J. Compliance of pediatric and adolescent cancer patients. Cancer 1986; 58: 117984.
  • 25
    Friedman IM, Litt IF, King DR, et al. Compliance with anticonvulsant therapy by epileptic youth: relationships to psychosocial aspects of adolescent development. J Adolesc Health Care 1986; 7: 127.
  • 26
    Friedman IM, Litt IF. Adolescents’ compliance with therapeutic regimens: psychological and social aspects and intervention. J Adolesc Health Care 1987; 8: 5267.
  • 27
    Michaud PA, Suris JC, Viner R. The adolescent with a chronic condition. Part II: Healthcare provision. Arch Dis Child 2004; 89: 9439.
  • 28
    Berry D, Bradlow A, Bersellini E. Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions. Rheumatology 2004; 43: 9015.
  • 29
    Barber N, Parson J, Clifford S, Darracott R, Horne R. Patients’ problems with new medication for chronic conditions. Qual Saf Health Care 2004; 13: 1725.
  • 30
    Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GA, Cohen A. Patient non-adherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 153544.
    Direct Link:
  • 31
    Stewart MA. Effective physician-patient communication and health outcome: a review. CMAJ 1995; 152 (Suppl. 9): 142333.
  • 32
    Trummer UF, Mueller UO, Nowak P. Does physician–patient communication that aims at empowering patients improve clinical outcome? A case study. Patient Educ Couns 2006; 61: 299306.
  • 33
    Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007; 26: 21725.